Evolus has signed an exclusive U.S. licensing agreement with IBSA for Profhilo, the Italian hybrid hyaluronic-acid injectable designed for skin quality and hydration rather than volumization. The deal carries no upfront payment, suggesting Evolus is betting on royalty-based returns over time. Profhilo operates on a different mechanism than traditional HA fillers—it's a low-viscosity, high-concentration HA product that spreads and integrates into the dermis, positioning it as a complement to neuromodulators and a competitor to products like Juvéderm Hydro and Restylane Vital.
Injectables
Evolus Secures Exclusive U.S. Profhilo License From IBSA — A Skin-Quality Play to Challenge Juvéderm
No upfront payment; 15-year term positions Evolus in the hydrating-filler segment.
No upfront payment; Evolus betting on royalty returns from a 15-year Profhilo license.
For practices, this expands Evolus' injectable portfolio beyond Jeuveau and creates another option in the crowded skin-quality space. Profhilo's clinical profile—multiple small-volume injections, 2-3 treatments per year, lower per-syringe revenue than traditional fillers—requires different patient education and pricing strategy. The 15-year term suggests Evolus sees long-term upside, but market penetration will depend on rebate aggressiveness and whether Allergan and Galderma defend their turf.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.